Derma Sciences Inc. (NASDAQ:DSCI) was up 2.6% on Thursday . The company traded as high as $4.04 and last traded at $4.01, with a volume of 121,827 shares traded. The stock had previously closed at $3.91.

The firm’s market cap is $109.24 million. The firm has a 50 day moving average price of $3.99 and a 200 day moving average price of $3.62.

Derma Sciences (NASDAQ:DSCI) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The business earned $20.20 million during the quarter, compared to the consensus estimate of $20.60 million. Equities research analysts anticipate that Derma Sciences Inc. will post ($0.20) earnings per share for the current year.

An institutional investor recently raised its position in Derma Sciences stock. Royce & Associates LLC boosted its position in Derma Sciences Inc. (NASDAQ:DSCI) by 7.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 237,507 shares of the company’s stock after buying an additional 16,000 shares during the period. Royce & Associates LLC owned 0.92% of Derma Sciences worth $1,085,000 as of its most recent SEC filing.

Derma Sciences, Inc (Derma Sciences) is a tissue regeneration company, which is engaged in the research and management of acute and chronic wounds, and burns. The Company operates through three segments: pharmaceutical wound care, advanced wound care and traditional wound care products. Pharmaceutical wound care products consist of DSC127, a product for the treatment of a variety of dermal applications, including diabetic foot ulcers and scar prevention.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.